Finoriq research workspace
Revolution Medicines, Inc. (RVMD) SEC Filings & Filing Highlights
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted. Review RVMD SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
- Company
- Revolution Medicines, Inc. (RVMD)
- Ticker
- RVMD
- Market Cap
- $38.7B
- Latest Price
- $181.88
- Industry
- Biotech & Pharma
Revolution Medicines, Inc. (RVMD) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Revolution Medicines, Inc. (RVMD).
| Event | Form | Date |
|---|---|---|
| Broker Non-VotesOn June 18, 2026, the Company held its annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockhol... | 8-K5.07 | 2026-06-22 |
| On June 18, 2026, Steve Kelsey, M.D., FRCP, FRCPath, informed Revolution Medicines, Inc. (the “...On June 18, 2026, Steve Kelsey, M.D., FRCP, FRCPath, informed Revolution Medicines, Inc. (the “Company”) of his intent to retire from his e... | 8-K5.02 | 2026-06-22 |
| Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progr...Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress | 8-K2.02 | 2026-05-06 |
| Revolution Medicines, Inc.: Corporate updateOn April 14, 2026, the Company entered into an underwriting agreement (the “Note Underwriting Agreement”) with J.P. Morgan Securities LLC,... | 8-K8.01 | 2026-04-17 |
| Revolution Medicines, Inc.: Material agreementOn April 17, 2026, Revolution Medicines, Inc. (the “Company”) issued $500,000,000 aggregate principal amount of its 0.50% Convertible Senio... | 8-K1.01 | 2026-04-17 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.